

=> fil reg

FILE 'REGISTRY' ENTERED AT 12:00:33 ON 10 AUG 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 AUG 2005 HIGHEST RN 859282-03-4

DICTIONARY FILE UPDATES: 9 AUG 2005 HIGHEST RN 859282-03-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*


Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d sta que l8

L3 STR



NODE ATTRIBUTES:

CONNECT IS M1 RC AT 10

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 1

NUMBER OF NODES IS 11


STEREO ATTRIBUTES: NONE

L5 3704 SEA FILE=REGISTRY CSS FUL L3
 L6 18 SEA FILE=REGISTRY ABB=ON PLU=ON L5 AND OC5/ES
 L7 8 SEA FILE=REGISTRY ABB=ON PLU=ON L6 AND ((PMS OR MXS)/CI OR
 C15H19NO8 OR C24H33NO9 OR C22H30N2O13 OR C21H39N7O12 OR
 C13H17NO5 OR C16H21NO9)
 L8 10 SEA FILE=REGISTRY ABB=ON PLU=ON L6 NOT L7

=> d l8 ide can tot

L8 ANSWER 1 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 709610-92-4 REGISTRY
 ED Entered STN: 14 Jul 2004
 CN Benzoic acid, 5-[(2-amino-2-deoxy- β -D-glucopyranosyl)amino]-2-hydroxy-
 (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C13 H18 N2 O7
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:65097

L8 ANSWER 2 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 709610-91-3 REGISTRY
 ED Entered STN: 14 Jul 2004
 CN Benzoic acid, 5-[[2-(acetylamino)-2-deoxy- β -D-galactopyranosyl]amino]-
 2-hydroxy- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C15 H20 N2 O8
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:65097

L8 ANSWER 3 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN
RN 709610-90-2 REGISTRY
ED Entered STN: 14 Jul 2004
CN Benzoic acid, 5-[[2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H20 N2 O8
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:65097

L8 ANSWER 4 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN
RN 709610-89-9 REGISTRY
ED Entered STN: 14 Jul 2004
CN Benzoic acid, 5-[(6-deoxy-L-galactopyranosyl)amino]-2-hydroxy- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H17 N O7

SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:65097

L8 ANSWER 5 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN
RN 709610-88-8 REGISTRY
ED Entered STN: 14 Jul 2004
CN Benzoic acid, 5-(β-D-galactopyranosylamino)-2-hydroxy- (9CI) (CA
INDEX NAME)
FS STEREOSEARCH
MF C13 H17 N O8
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


REFERENCE 1: 141:65097

L8 ANSWER 6 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN
RN 709610-87-7 REGISTRY
ED Entered STN: 14 Jul 2004
CN Benzoic acid, 5-[[2-(acetylamino)-4-O-[2-(acetylamino)-2-deoxy-β-D-

glucopyranosyl]-2-deoxy- β -D-glucopyranosyl]amino]-2-hydroxy- (9CI)
(CA INDEX NAME)

FS STEREOSEARCH
MF C23 H33 N3 O13
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:65097

L8 ANSWER 7 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN
RN 709610-86-6 REGISTRY
ED Entered STN: 14 Jul 2004
CN Benzoic acid, 5-[(4-O- β -D-glucopyranosyl- β -D-glucopyranosyl)amino]-2-hydroxy- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H27 N O13
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

jan delaval - 10 august 2005

REFERENCE 1: 141:65097

L8 ANSWER 8 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 709610-85-5 REGISTRY
 ED Entered STN: 14 Jul 2004
 CN Benzoic acid, 5-[(4-O-β-D-galactopyranosyl-β-D-glucopyranosyl)amino]-2-hydroxy- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C19 H27 N O13
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:65097

L8 ANSWER 9 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 709610-84-4 REGISTRY
 ED Entered STN: 14 Jul 2004
 CN Benzoic acid, 5-[(4-O-α-D-glucopyranosyl-β-D-glucopyranosyl)amino]-2-hydroxy- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C19 H27 N O13
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:65097

L8 ANSWER 10 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN
RN 123135-21-7 REGISTRY
ED Entered STN: 13 Oct 1989
CN Benzoic acid, 5-(β -D-glucopyranosylamino)-2-hydroxy- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H17 N O8
SR CA
LC STN Files: CA, CAPLUS, MEDLINE, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)


REFERENCE 1: 141:65097

REFERENCE 2: 115:247335

REFERENCE 3: 115:247332

REFERENCE 4: 111:166711

=> => d sta que 116
L3 STR



NODE ATTRIBUTES:


CONNECT IS M1 RC AT 10
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 1
 NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

L5 3704 SEA FILE=REGISTRY CSS FUL L3
 L13 STR



VAR G1=O/N

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE

L15 3 SEA FILE=REGISTRY SUB=L5 SSS FUL L13
 L16 2 SEA FILE=REGISTRY ABB=ON PLU=ON L15 NOT NC5/ES

=> d l16 ide can tot

L16 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2005 ACS on STN

RN 104787-24-8 REGISTRY

ED Entered STN: 18 Oct 1986

CN Benzoic acid, 5-(D-glucuronoylamino)-2-hydroxy-, compd. with 1H-imidazole
 (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1H-Imidazole, mono[5-(D-glucuronoylamino)-2-hydroxybenzoate] (9CI)

FS STEREOSEARCH


MF C13 H15 N O9 . C3 H4 N2

SR CA
LC STN Files: CA, CAPLUS

CM 1


CRN 104786-98-3
CMF C13 H15 N O9

Absolute stereochemistry.



CM 2

CRN 288-32-4
CMF C3 H4 N2




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 105:165010

L16 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2005 ACS on STN
RN 104786-98-3 REGISTRY
ED Entered STN: 18 Oct 1986
CN Benzoic acid, 5-(D-glucuronoylamino)-2-hydroxy- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H15 N O9
CI COM
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 105:165010


=> => d sta que l12
L3 STR



NODE ATTRIBUTES:
CONNECT IS M1 RC AT 10
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 1
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE
L5 3704 SEA FILE=REGISTRY CSS FUL L3
L10 STR



NODE ATTRIBUTES:

CONNECT IS E2 RC AT 2
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 1
 NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE


L12 0 SEA FILE=REGISTRY SUB=L5 SSS FUL L10

100.0% PROCESSED 3704 ITERATIONS
 SEARCH TIME: 00.00.01

0 ANSWERS

=> d sta que 19

L3 STR



NODE ATTRIBUTES:

CONNECT IS M1 RC AT 10
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 1
 NUMBER OF NODES IS 11


STEREO ATTRIBUTES: NONE

L5 3704 SEA FILE=REGISTRY CSS FUL L3
 L9 14 SEA FILE=REGISTRY ABB=ON PLU=ON L5 AND C2H4O


=> d scan 19

L9 14 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Benzoic acid, 2-hydroxy-5-[(4-hydroxyphenyl)azo]-, polymer with
 1,6-diisocyanatohexane and α -hydro- ω -hydroxypoly(oxy-1,2-
 ethanediyl), block (9CI)
 MF (C13 H10 N2 O4 . C8 H12 N2 O2 . (C2 H4 O)n H2 O)x
 CI PMS


CM 1



CM 2



CM 3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):13


L9 14 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, homopolymer, ester with
 α -(carboxymethyl)- ω -(carboxymethoxy)poly(oxy-1,2-ethanediyl),
 compd. with 5-amino-2-hydroxybenzoic acid (2:1:?) (9CI)
 MF C7 H7 N O3 . x (C6 H8 O7)x . x (C2 H4 O)n C4 H6 O5

CM 1




CM 2

CM 3




CM 4

CM 5




L9 14 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Benzoic acid, 2-hydroxy-5-[(2-methyl-1-oxo-2-propenyl)amino]-, polymer
 with 1,2-ethanediylbis(oxy-2,1-ethanediyl) bis(2-methyl-2-propenoate),
 2-hydroxyethyl 2-methyl-2-propenoate and α,α' -[(1-methylethylidene)di-4,1-phenylene]bis[ω -[(2-methyl-1-oxo-2-propenyl)oxy]poly(oxy-1,2-ethanediyl)] (9CI)
 MF (C14 H22 O6 . C11 H11 N O4 . C6 H10 O3 . (C2 H4 O)n (C2 H4 O)n C23
 H24 O4)x
 CI PMS

CM 1




CM 2


PAGE 1-A




PAGE 1-B



CM 3




CM 4




L9 14 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-,
 2-[(2-methyl-1-oxo-2-propenyl)oxy]ethyl ester, polymer with 2-hydroxyethyl
 2-methyl-2-propenoate, 2-hydroxy-5-[(2-methyl-1-oxo-2-
 propenyl)amino]benzoic acid, α,α' -[(1-methylethylidene)di-4,1-
 phenylene]bis[ω -[(2-methyl-1-oxo-2-propenyl)oxy]poly(oxy-1,2-
 ethanediyl)] and methyl 2-methyl-2-propenoate (9CI)
 MF (C15 H12 O7 . C11 H11 N O4 . C6 H10 O3 . C5 H8 O2 . (C2 H4 O)n (C2 H4
 O)n C23 H24 O4)x
 CI PMS

CM 1




CM 2




CM 3


PAGE 1-A



PAGE 1-B



CM 4





$$\begin{array}{c} \text{H}_2\text{C} \quad \text{O} \cdot \\ \parallel \quad \parallel \\ \text{Me}-\text{C}-\text{C}-\text{OMe} \end{array}$$


CM 1

$$\begin{array}{c}
 \text{HO}_2\text{C}-\text{CH}_2-\text{C}(\text{CO}_2\text{H})-\text{O}-\text{C}(=\text{O})-\text{CH}_2-\text{C}(\text{R})-\text{O}-\text{C}(=\text{O})-\text{CH}_2- \left[\text{O}-\text{CH}_2-\text{CH}_2 \right]_n -\text{O}-\text{CH}_2-\text{C}(=\text{O})- \\
 \text{HO}_2\text{C}-\text{CH}_2-\text{C}(\text{CO}_2\text{H})-\text{O}-\text{C}(=\text{O})-\text{CH}_2-\text{C}(\text{R})-\text{O}-\text{C}(=\text{O})-\text{CH}_2- \left[\text{O}-\text{CH}_2-\text{CH}_2 \right]_n -\text{O}-\text{CH}_2-\text{C}(=\text{O})- \\
 \text{C}(\text{O})-\text{O}-\text{C}(\text{CH}_2\text{CO}_2\text{H})(\text{CO}_2\text{H})-\text{CH}_2-\text{CO}_2\text{H} \\
 \text{R}-\text{CH}_2-\text{C}(=\text{O})-\text{O}-\text{C}(\text{CH}_2\text{CO}_2\text{H})(\text{CO}_2\text{H})-\text{CH}_2-\text{CO}_2\text{H}
 \end{array}$$
$$\begin{array}{c}
 \text{R3} \\
 | \\
 -\text{O}-\text{C}-\text{R2} \\
 | \\
 \text{CH}_2-\text{C}-\text{O}-\text{C}-\text{CH}_2-\text{CO}_2\text{H} \\
 || \quad | \\
 \text{O} \quad \text{CH}_2-\text{CO}_2\text{H}
 \end{array}$$

PAGE 2-A




CM 2




L9 14 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy-, ether with
 2-hydroxy-5-[[4-[(2-hydroxyethyl)[(2-hydroxyethyl)[2-methoxy-4-[(3-sulfophenyl)azo]phenyl]amino]carbonyl]amino]phenyl]azo]benzoic acid (2:1)
 (9CI)
 MF (C2 H4 O)_n (C2 H4 O)_n C31 H30 N6 O10 S
 CI PMS, COM

PAGE 1-A




PAGE 1-B




L9 14 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Benzoic acid, 2-hydroxy-5-[(2-methyl-1-oxo-2-propenyl)amino]-, polymer
 with 1,2-ethanediyl bis(2-methyl-2-propenoate), 2-hydroxyethyl
 2-methyl-2-propenoate, [3-[(2-methyl-1-oxo-2-propenyl)amino]phenyl]boronic
 acid and α -(2-methyl-1-oxo-2-propenyl)- ω -methoxypoly(oxy-1,2-
 ethanediyl) (9CI)
 MF (C11 H11 N O4 . C10 H14 O4 . C10 H12 B N O3 . C6 H10 O3 . (C2 H4 O)_n
 C5 H8 O2)x
 CI PMS


CM 1




CM 2




CM 3



CM 4



CM 5




L9 14 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

IN Benzoic acid, 2-hydroxy-5-[(2-methyl-1-oxo-2-propenyl)amino]-, polymer with α, α' -[(1-methylethylidene)di-4,1-phenylene]bis[ω -[(2-methyl-1-oxo-2-propenyl)oxy]poly(oxy-1,2-ethanediyl)] and trimethyl-4,13-dioxo-3,14-dioxa-5,12-diazahehexadecane-1,16-diyl bis(2-methyl-2-propenoate) (9CI)

MF (C23 H38 N2 O8 . C11 H11 N O4 . (C2 H4 O)n (C2 H4 O)n C23 H24 O4)x


CI PMS

CM 1




3 (D1-Me)

CM 2




CM 3

PAGE 1-A




PAGE 1-B





L9 14 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Poly(oxy-1,2-ethanediyl), α, α' -[[[2-[[4'-[(3-carboxy-4-hydroxyphenyl)azo]-3,3'-dimethyl[1,1'-biphenyl]-4-yl]azo]-1-naphthalenyl]imino]di-2,1-ethanediyl]bis[ω -hydroxy-, monosodium salt (9CI)
 MF (C2 H4 O)n (C2 H4 O)n C35 H33 N5 O5 . Na
 CI PMS

PAGE 1-A



● Na


PAGE 1-B




L9 14 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Benzoic acid, 5-amino-2-hydroxy-, compd. with α -[2-[1,2-dicarboxy-1-(carboxymethyl)ethoxy]-2-oxoethyl]- ω -[2-[1,2-dicarboxy-1-(carboxymethyl)ethoxy]-2-oxoethoxy]poly(oxy-1,2-ethanediyl) (9CI)
 MF C7 H7 N O3 . x (C2 H4 O)_n C16 H18 O17

CM 1


PAGE 1-A



PAGE 1-B




CM 2





L9 14 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Poly(oxy-1,2-ethanediyl), α,α' -[[[2-[[4'-[(3-carboxy-4-hydroxyphenyl)azo]-3,3'-dimethyl[1,1'-biphenyl]-4-yl]azo]-1-naphthalenyl]imino]di-2,1-ethanediyl]bis[ω -hydroxy- (9CI)
 MF (C2 H4 O)_n (C2 H4 O)_n C35 H33 N5 O5
 CI PMS, COM

PAGE 1-A




PAGE 1-B




L9 14 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-, 2-[(2-methyl-1-oxo-2-propenyl)oxy]ethyl ester, polymer with 2-hydroxy-5-[(2-methyl-1-oxo-2-propenyl)amino]benzoic acid and α -(2-methyl-1-oxo-2-propenyl)- ω -[(2-methyl-1-oxo-2-propenyl)oxy]poly(oxy-1,2-ethanediyl) (9CI)
 MF (C15 H12 O7 . C11 H11 N O4 . (C2 H4 O)_n C8 H10 O3)_x
 CI PMS


CM 1



CM 2




CM 3




L9 14 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,2,4-Benzenetricarboxylic acid, 4-[2-[(2-methyl-1-oxo-2-propenyl)oxy]ethyl] ester, polymer with 2-hydroxyethyl 2-methyl-2-propenoate, 2-hydroxy-5-[(2-methyl-1-oxo-2-propenyl)amino]benzoic acid, α,α' -[(1-methylethylidene)di-4,1-phenylene]bis[ω -[(2-methyl-1-oxo-2-propenyl)oxy]poly(oxy-1,2-ethanediyl)] and methyl 2-methyl-2-propenoate (9CI)
 MF (C15 H14 O8 . C11 H11 N O4 . C6 H10 O3 . C5 H8 O2 . (C2 H4 O)n (C2 H4 O)n C23 H24 O4)x
 CI PMS

CM 1




CM 2




CM 3


PAGE 1-A




PAGE 1-B



CM 4




CM 5




L9 14 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy-, ether with
 2-hydroxy-5-[[4-[(2-hydroxyethyl)[(2-hydroxyethyl)[2-methoxy-4-[(3-sulphophenyl)azo]phenyl]amino]carbonyl]amino]phenyl]azo]benzoic acid (2:1),
 disodium salt (9CI)
 MF (C2 H4 O)_n (C2 H4 O)_n C31 H30 N6 O10 S . 2 Na
 CI PMS

PAGE 1-A



● 2 Na

PAGE 1-B




ALL ANSWERS HAVE BEEN SCANNED

=> => d l48 ide can

L48 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 89-57-6 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN Benzoic acid, 5-amino-2-hydroxy- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Salicylic acid, 5-amino- (8CI)
 OTHER NAMES:
 CN 2-Hydroxy-5-aminobenzoic acid
 CN 3-Carboxy-4-hydroxyaniline
 CN 5-Amino-2-hydroxybenzoic acid
 CN 5-Aminosalicylic acid
 CN 5-ASA
 CN Asacol
 CN Asacolitin
 CN Asacolon
 CN Canasa
 CN Claversal
 CN Fisalamine
 CN Lixacol
 CN m-Aminosalicylic acid

CN Mesacol
CN Mesalamine
CN Mesalazine
CN Mesasal
CN NSC 38877
CN Pentasa
CN Rowasa
CN Salofalk
CN Salozinal
FS 3D CONCORD
DR 61513-32-4
MF C7 H7 N O3
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS,
BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,
CHEMINFORMRX, CHEMLIST, CIN, CSCHM, CSNB, DDFU, DIOGENES, DRUGU,
EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH,
IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS,
PHAR, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USAN,
USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1807 REFERENCES IN FILE CA (1907 TO DATE)
93 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1817 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 143:120187
REFERENCE 2: 143:109788
REFERENCE 3: 143:103254
REFERENCE 4: 143:93599
REFERENCE 5: 143:83476
REFERENCE 6: 143:71426
REFERENCE 7: 143:71311
REFERENCE 8: 143:70797
REFERENCE 9: 143:55860

REFERENCE 10: 143:53231

=> d his

(FILE 'HOME' ENTERED AT 11:16:54 ON 10 AUG 2005)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 11:17:04 ON 10 AUG 2005

L1 1 S US20040121967/PN OR (US2003-688585# OR US2002-435964#)/AP,PRN
SEL RN

FILE 'REGISTRY' ENTERED AT 11:17:31 ON 10 AUG 2005

L2 15 S E1-E15
L3 STR
L4 50 S L3 CSS
L5 3704 S L3 CSS FUL
SAV L5 WHITE688/A
L6 18 S L5 AND OC5/ES
L7 8 S L6 AND ((PMS OR MXS)/CI OR C15H19NO8 OR C24H33NO9 OR C22H30N2
L8 10 S L6 NOT L7
SAV L8 WHITE688A/A
L9 14 S L5 AND C2H4O
L10 STR L3
L11 0 S L10 SAM SUB=L5
L12 0 S L10 FUL SUB=L5
SAV L12 WHITE688B/A
L13 STR L3
L14 0 S L13 SAM SUB=L5
L15 3 S L13 FUL SUB=L5
SAV L15 WHITE688C/A
L16 2 S L15 NOT NC5/ES

FILE 'HCAOLD' ENTERED AT 11:35:42 ON 10 AUG 2005

L17 0 S L8 OR L16

FILE 'HCAPLUS' ENTERED AT 11:35:48 ON 10 AUG 2005

L18 5 S L8 OR L16
E NELSON D/AU
L19 185 S E3,E16
E NELSON DEANA/AU
L20 47 S E4-E7
L21 1 S L18 AND L19,L20
L22 5 S L18,L21

FILE 'USPATFULL' ENTERED AT 11:36:58 ON 10 AUG 2005

L23 1 S L8 OR L16

FILE 'REGISTRY' ENTERED AT 11:37:04 ON 10 AUG 2005

E DEOXYMALTOBIOSE/CN
E 1-DEOXYMALTOBIOSE/CN
E 1-DEOXYLACTOBIOSE/CN
E DEOXYLACTOBIOSE/CN
E DEOXYCELLOBIOSE/CN
E N,N-DIACETYL-1-DEOXYCHITOBIOSE/CN
E 1-DEOXYGLUCOSE/CN
E 1-DEOXYGALACTOSE/CN
E 1-DEOXYFUCOSE/CN
E 1-DEOXYFRUCTOSE/CN
L24 1 S E3

E N-ACETYL-1-DEOXYGLUCOSAMINE/CN
 E N-ACETYL-1-DEOXYGALACTOSEAMINE/CN
 L25 9 S (MALTOBIOISE OR LACTOBIOSE OR CELLOBIOISE OR GLUCOSE OR GALAC
 E N-ACETYL-1-GLUCOSAMINE/CN
 E N-ACETYL-GLUCOSAMINE/CN
 E N-ACETYLGLUCOSAMINE/CN
 L26 1 S E3
 E N-ACETYLALACTOSAMINE/CN
 L27 2 S E3
 L28 4 S (L-GLUCOSE OR L-GALACTOSE OR D-FUCOSE OR L-FRUCTOSE)/CN
 E C8H15NO6/MF
 L29 16 S E3 AND GLUCOSE AND 2 ACETYLAMINO 2 DEOXY
 L30 8 S L29 NOT ((T OR D)/ELS OR OC5/ES)
 L31 2 S L30 NOT (LABELED OR 13C# OR 14C#)
 L32 8 S E3 AND GALACTOSE AND 2 ACETYLAMINO 2 DEOXY
 L33 3 S L32 NOT (LABELED OR (T OR D)/ELS OR 13C# OR 14C#)
 L34 1 S L2 AND C6H12O5
 L35 1 S L2 AND C6H13NO5
 E C6H13NO5/MF
 L36 3 S E3 AND GLUCOPYRANOSYLAMINE
 E LACTOBIOSE/CN
 L37 1 S E3
 E C12H22O11/MF
 L38 21 S E3 AND GLUCOSE AND GALACTOPYRANOSYL
 L39 12 S L38 AND 4
 L40 2 S L39 NOT (LABELED OR 14C# OR (T OR D)/ELS OR 13C#)
 E MALTOBIOSE/CN
 L41 1 S E3
 E C12H22O11/MF
 L42 14 S E3 AND GLUCOSE AND GLUCOPYRANOSYL AND 4
 L43 8 S L42 NOT (LABELED OR (T OR D)/ELS OR 13C# OR 14C#)
 L44 7 S L43 NOT 180
 E CHITOBIOSE/CN
 L45 1 S E5
 E C16H28N2O11/MF
 L46 8 S E3 AND GLUCOSE AND 2 ACETYLAMINO AND 2 DEOXY AND GLUCOPYRANOS
 L47 2 S L46 AND 4
 L48 1 S 89-57-6
 L49 1 S 25322-68-3

FILE 'HCAPLUS' ENTERED AT 11:57:01 ON 10 AUG 2005

L50 1817 S L48
 L51 54 S L49 AND L50
 L52 53 S L25-L28, L31, L33-L37, L40, L41, L44, L45, L47 AND L50
 L53 4 S L48 (L) RACT+NT/RL AND L51, L52
 L54 2 S L49 (L) RACT+NT/RL AND L51
 L55 6 S L25-L28, L31, L33-L37, L40, L41, L44, L45, L47 (L) RACT+NT/RL AND L52
 L56 7 S L53-L55
 L57 11 S L22, L56
 SEL DN AN 5 6
 L58 9 S L57 NOT E1-E6

FILE 'REGISTRY' ENTERED AT 12:00:33 ON 10 AUG 2005

=> fil uspatful

FILE 'USPATFULL' ENTERED AT 12:02:45 ON 10 AUG 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 9 Aug 2005 (20050809/PD)

FILE LAST UPDATED: 9 Aug 2005 (20050809/ED)

jan delaval - 10 august 2005

HIGHEST GRANTED PATENT NUMBER: US6928656
 HIGHEST APPLICATION PUBLICATION NUMBER: US2005172377
 CA INDEXING IS CURRENT THROUGH 9 Aug 2005 (20050809/UPCA)
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 9 Aug 2005 (20050809/PD)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2005
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2005

```
>>> USPAT2 is now available.  USPATFULL contains full text of the      <<<
>>> original, i.e., the earliest published granted patents or          <<<
>>> applications.  USPAT2 contains full text of the latest US          <<<
>>> publications, starting in 2001, for the inventions covered in      <<<
>>> USPATFULL.  A USPATFULL record contains not only the original      <<<
>>> published document but also a list of any subsequent                <<<
>>> publications.  The publication number, patent kind code, and       <<<
>>> publication date for all the US publications for an invention      <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL    <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc.                                                           <<<

>>> USPATFULL and USPAT2 can be accessed and searched together        <<<
>>> through the new cluster USPATALL.  Type FILE USPATALL to          <<<
>>> enter this cluster.                                                <<<
>>>                                                                    <<<
>>> Use USPATALL when searching terms such as patent assignees,       <<<
>>> classifications, or claims, that may potentially change from      <<<
>>> the earliest to the latest publication.                             <<<
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l23 bib abs hitstr

```
L23  ANSWER 1 OF 1  USPATFULL on STN
AN    2004:159163  USPATFULL
TI    Aminosalicylate derivatives for treatment of inflammatory bowel disease
IN    Nelson, Deanna Jean, Cary, NC, UNITED STATES
PI    US 2004121967      A1    20040624
AI    US 2003-688585      A1    20031018 (10)
PRAI  US 2002-435964P      20021221 (60)
DT    Utility
FS    APPLICATION
LREP  Deanna J. Nelson, Ph.D., 104 Tasman Court, Cary, NC, 27513
CLMN  Number of Claims: 18
ECL   Exemplary Claim: 1
DRWN  No Drawings
LN.CNT 1199
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB    Therapeutic 5-aminosalicylic acid derivative compositions having general
      formula (I), wherein R is a 1-deoxy sugar residue or a poly(ethylene
      glycol) chain-containing residue, are provided. The compositions enable
      topical delivery of 5-aminosalicylic acid to the gastrointestinal tract
      following oral administration in pharmaceutical preparations. According
      to the invention, the compositions stabilize pharmaceutical compositions
      containing therapeutic 5-aminosalicylic acid derivatives in a manner
      that enhances the retention of said compositions in the intestine,
      decreases the cellular absorption thereof, and decreases the transfer of
      said compositions or the 5-aminosalicylic acid derived therefrom to the
      systemic circulation.  ##STR1##
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 123135-21-7P 709610-92-4P

(aminosalicylate derivs. for treatment of inflammatory bowel disease)

RN 123135-21-7 USPATFULL

CN Benzoic acid, 5-(β -D-glucopyranosylamino)-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 709610-92-4 USPATFULL

CN Benzoic acid, 5-[(2-amino-2-deoxy- β -D-glucopyranosyl)amino]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 709610-84-4 709610-85-5 709610-86-6

709610-87-7 709610-88-8 709610-89-9


709610-90-2 709610-91-3

(aminosalicylate derivs. for treatment of inflammatory bowel disease)

RN 709610-84-4 USPATFULL

CN Benzoic acid, 5-[(4-O- α -D-glucopyranosyl- β -D-glucopyranosyl)amino]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 709610-85-5 USPATFULL

CN Benzoic acid, 5-[(4-O- β -D-galactopyranosyl- β -D-glucopyranosyl)amino]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 709610-86-6 USPATFULL

CN Benzoic acid, 5-[(4-O- β -D-glucopyranosyl- β -D-glucopyranosyl)amino]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 709610-87-7 USPATFULL

CN Benzoic acid, 5-[[2-(acetylamino)-4-O-[2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]-2-deoxy- β -D-glucopyranosyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 709610-88-8 USPATFULL

CN Benzoic acid, 5-(β -D-galactopyranosylamino)-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 709610-89-9 USPATFULL

CN Benzoic acid, 5-[(6-deoxy-L-galactopyranosyl)amino]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 709610-90-2 USPATFULL

CN Benzoic acid, 5-[[2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 709610-91-3 USPATFULL

CN Benzoic acid, 5-[[2-(acetylamino)-2-deoxy- β -D-galactopyranosyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 12:03:34 ON 10 AUG 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Aug 2005 VOL 143 ISS 7

FILE LAST UPDATED: 9 Aug 2005 (20050809/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l58 all hitstr tot

L58 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:591060 HCAPLUS

DN 142:148136

ED Entered STN: 25 Jul 2004

TI Protective effects of some azo derivatives of 5-aminosalicylic acid and their pegylated prodrugs on acetic acid-induced rat colitis

AU Garjani, Alireza; Davaran, Soodabeh; Rashidi, Mohamadreza; Maleki, Nasrin

CS Department of Pharmacology, School of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran

SO Daru, Journal of Faculty of Pharmacy, Tehran University of Medical Sciences (2004), 12(1), 24-30

CODEN: DJTSFE; ISSN: 1560-8115

PB Tehran University of Medical Sciences, Faculty of Pharmacy

DT Journal

LA English

CC 1-7 (Pharmacology)

AB The protective and anti-inflammatory effects of azo and azo-linked polymeric prodrugs of 5-aminosalicylic acid (5-ASA) on acetic acid induced colitis in rats were investigated. Three azo prodrugs;

4,4'-dihydroxy-azobenzene-3-carboxylic acid (azo compound I), 4-hydroxy-azobenzene-3,4'-dicarboxylic acid (azo compound II), 4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid (azo compound III) and their polyethylene glycol (PEG 6000) derivs. were synthesized. Rats were pretreated orally (1 h prior to induction of colitis) with sulfasalazin (300 mg/kg), azo compds. I, II, III and polyethylene glycol conjugates of azo compds. II and III in doses which had the same amount of 5-ASA as sulfasalazin contains. The colonic damage was examined 24 h later and characterized by gross microscopic injury and colonic edema. Among prodrugs only azo compound III (215 mg/kg) produced a significant ($p < 0.01$) protective effect against colonic injury comparable with sulfasalazin. Doubling the dose (430 mg/kg) showed more anti-colitis effects. Polyethylene glycol conjugate of azo compds. II and III also showed reduction in the extent of the cell death and tissue disorganization similar to sulfasalazin. While neither sulfasalazin, nor azo compound II and its PEG polymer produced anti-edema effects, both azo compound III and its PEG polymer decreased colon edema significantly ($p < 0.05$). Histol. examns. also indicated a marked reduction in tissue injury and inhibition in neutrophil infiltration in rats treated with azo compound III and PEG conjugates of azo compds. II and III. Results of this investigation provide exptl. evidence supporting new cytoprotective, antiinflammatory and anti-edema properties of the azo derivs. of 5-ASA and their PEGylated prodrugs.

- ST aminosalicic acid polyethylene glycol deriv colitis antiinflammatory neutrophil infiltration
- IT Cytoprotective agents
 - (4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid had better cytoprotection in rat colitis model with high anti-inflammatory, anti-edema activity compared to other azo-derivs. of 5-ASA and their PEG derivs.)
- IT Polyoxyalkylenes, biological studies
 - RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
 - (4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid had better protection in acetic acid-induced rat colitis model with high anti-inflammatory, anti-edema activity compared to PEG-4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid)
- IT Anti-inflammatory agents
 - (4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid had better protection in rat colitis model with high anti-inflammatory activity compared to other azo-derivs. of 5-ASA and their PEG derivs.)
- IT Inflammation
 - Intestine, disease
 - (colitis; 4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid showed better protection in rat model of colitis with higher anti-inflammatory, anti-edema activity compared to other azo-derivs. of 5-aminosalicylic acid and their PEG derivs.)
- IT Intestine
 - (colon; 4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid showed better protection in rat model of colitis with higher anti-inflammatory, activity compared to other azo-derivs. of 5-aminosalicylic acid and their PEG derivs.)
- IT Neutrophil
 - (infiltration; 4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid had better protection in acetic acid-induced rat colitis model with high anti-inflammatory, anti-edema activity compared to PEG-4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid)
- IT Cell migration
 - (neutrophil infiltration; 4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid had better protection in acetic acid-induced rat


- colitis model with high anti-inflammatory, anti-edema activity compared to PEG-4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid)
- IT 259151-72-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid had better protection in acetic acid-induced rat colitis model with high anti-inflammatory, anti-edema activity compared to 4,4'-dihydroxy-azobenzene-3-carboxylic acid)
- IT 64896-26-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid had better protection in acetic acid-induced rat colitis model with high anti-inflammatory, anti-edema activity compared to 4-hydroxy-azobenzene-3,4'-dicarboxylic acid)
- IT 25322-68-3, Polyethylene glycol
RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid had better protection in acetic acid-induced rat colitis model with high anti-inflammatory, anti-edema activity compared to PEG-4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid)
- IT 827613-91-2DP, ethoxylated conjugate derivs.
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid had better protection in acetic acid-induced rat colitis model with high anti-inflammatory, anti-edema activity compared to PEG-4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid)
- IT 69-72-7, Salicylic acid, reactions 150-13-0, p-Aminobenzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid had better protection in acetic acid-induced rat colitis model with high anti-inflammatory, anti-edema activity compared to PEG-4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid)
- IT 90-02-8, Salicylic aldehyde, reactions 123-30-8, p-Aminophenol
RL: RCT (Reactant); RACT (Reactant or reagent)
(4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid had better protection in acetic acid-induced rat colitis model with high anti-inflammatory, anti-edema activity compared to PEG-4,4'-dihydroxy-azobenzene-3-carboxylic acid)
- IT 259151-72-9DP, ethoxylated conjugate derivs.
RL: SPN (Synthetic preparation); PREP (Preparation)
(4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid had better protection in acetic acid-induced rat colitis model with high anti-inflammatory, anti-edema activity compared to PEG-4,4'-dihydroxy-azobenzene-3-carboxylic acid)
- IT 64896-26-0DP, ethoxylated conjugate derivs.
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid had better protection in acetic acid-induced rat colitis model with high anti-inflammatory, anti-edema activity compared to PEG-4-hydroxy-azobenzene-3,4'-dicarboxylic acid)

- IT 64-19-7, Acetic acid, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid had better protection in acetic acid-induced rat colitis model with high anti-inflammatory, anti-edema activity compared to other azo-derivs. of 5-ASA and their PEG derivs.)
- IT 827613-91-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid showed better protection in rat model of colitis with higher anti-inflammatory, anti-edema activity compared to other azo-derivs. of 5-aminosalicylic acid and their PEG derivs.)
- IT 827613-91-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid showed better protection in rat model of colitis with higher anti-inflammatory, anti-edema activity compared to other azo-derivs. of 5-aminosalicylic acid and their PEG derivs.)
- RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
- RE
- (1) Boni, B; Current News 2002, V781, P402
 - (2) Brown, J; Am J Med Chem 1983, V26, P1300 HCAPLUS
 - (3) Brown, J; Appl Environ Microbiol 1981, V41, P1283 HCAPLUS
 - (4) Callant, D; Makromol Chem 1990, V191, P529 HCAPLUS
 - (5) Cameron, J; Am J Physiol 1995, V268, PG622
 - (6) Chng, K; Appl Environ Microbiol 1976, V5, P558
 - (7) Christensen, L; Br J Clin Pharmacol 1987, V23, P365 HCAPLUS
 - (8) Collier, H; Prostaglandins 1976, V11, P217
 - (9) Crotty, B; Br J Clin Pharmacol 1992, V34, P189 MEDLINE
 - (10) Davaran, S; AAPS Pharm Sci Tech 2001, V2(4) HCAPLUS
 - (11) Davaran, S; J Control Release 1999, V58, P279 HCAPLUS
 - (12) Dieckhues, B; Zentralbl Bakteriell Parasiten Kd 1960, V180, P244 HCAPLUS
 - (13) Dubru, D; Xenobiotica 1975, V5, P563
 - (14) Friend, D; Adv Drug Deliv Rev 1991, V7, P149 HCAPLUS
 - (15) Fuller, A; Lancet 1937, V1, P194
 - (16) Geier, D; Am J Med 1992, V93, P199 MEDLINE
 - (17) Hanohan, T; Xenobiotica 1977, V7, P765
 - (18) Jarnerol, G; Drugs 1989, V37, P73
 - (19) Kamm, M; Br Med J 1992, V305, P35 MEDLINE
 - (20) Lloyd, A; Int J Pharm 1994, V106, P255 HCAPLUS
 - (21) MacDermott, P; Gastroenterology 1989, V96, P442
 - (22) MacDermott, P; The Am J Gastroenterol 2000, V95, P3343
 - (23) Miyadera, T; The chemistry of hydraz, Azo and Azoxy compounds. Part 1 1975, P495 HCAPLUS
 - (24) Myers; Am J Physiol 1997, V273, PG928 HCAPLUS
 - (25) Peppercorn, M; J Pharmacol Exp Ther 1972, V181, P555 HCAPLUS
 - (26) Radomski, J; J Pharmacol Exp Ther 1962, V136, P259 HCAPLUS
 - (27) Rusmussen, S; Gastroenterology 1982, V83, P1062
 - (28) Schacht, E; J Control Rel 1996, V39, P327 HCAPLUS
 - (29) Schroder, H; Xenobiotica 1973, V3, P233 MEDLINE
 - (30) Schroeder, H; Clin Pharmacol Ther 1972, V13, P539
 - (31) Sharon, P; Gastroenterology 1978, V75, P638 HCAPLUS
 - (32) Walker, R; Food Cosmet Toxicol 1970, V8, P659 HCAPLUS
- IT 25322-68-3, Polyethylene glycol
 RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or

reagent); USES (Uses)

(4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid had better protection in acetic acid-induced rat colitis model with high anti-inflammatory, anti-edema activity compared to PEG-4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid)

RN 25322-68-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (9CI) (CA INDEX NAME)


IT 89-57-6, 5-Aminosalicylic acid

RL: RCT (Reactant); RACT (Reactant or reagent)

(4,4'-dihydroxy-3'-formyl-azobenzene-3-carboxylic acid showed better protection in rat model of colitis with higher anti-inflammatory, anti-edema activity compared to other azo-derivs. of 5-aminosalicylic acid and their PEG derivs.)

RN 89-57-6 HCAPLUS

CN Benzoic acid, 5-amino-2-hydroxy- (9CI) (CA INDEX NAME)



L58 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:513316 HCAPLUS

DN 141:65097

ED Entered STN: 25 Jun 2004

TI Aminosalicylate derivatives for treatment of inflammatory bowel disease

IN Nelson, Deanna Jean

PA USA

SO U.S. Pat. Appl. Publ., 13 pp.

CODEN: USXXCO

DT Patent

LA English

IC ICM C08B037-00

ICS C07H005-04

INCL 514042000; 514159000; 536018700; 525526000

CC 1-7 (Pharmacology)

Section cross-reference(s): 33, 63


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004121967	A1	20040624	US 2003-688585	20031018
PRAI	US 2002-435964P	P	20021221		

CLASS


PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
-----	-----	-----

US 2004121967 ICM C08B037-00
 ICS C07H005-04
 INCL 514042000; 514159000; 536018700; 525526000
 US 2004121967 NCL 514/042.000; 514/159.000; 536/018.700; 525/526.000
 OS MARPAT 141:65097
 GI




- AB Compns. containing therapeutic 5-aminosalicylic acid derivs. I [R = 1-deoxy sugar residue, poly(ethylene glycol) chain-containing residue] are provided. The compns. enable topical delivery of 5-aminosalicylic acid to the gastrointestinal tract following oral administration in pharmaceutical preps. According to the invention, the compns. stabilize pharmaceutical compns. containing therapeutic 5-aminosalicylic acid derivs. in a manner that enhances the retention of the compns. in the intestine, decreases the cellular absorption thereof, and decreases the transfer of the compns. or the 5-aminosalicylic acid derived therefrom to the systemic circulation.
- ST aminosalicylate sugar deriv inflammatory bowel disease; PEG aminosalicylate deriv inflammatory bowel disease
- IT Disaccharides
 Monosaccharides
 Polysaccharides, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (1-deoxy, conjugates with 5-aminosalicylic acid; aminosalicylate derivs. for treatment of inflammatory bowel disease)
- IT Alkylation
 Anti-inflammatory agents
 Drug delivery systems
 Gastrointestinal agents
 Human
 Inflammation
 (aminosalicylate derivs. for treatment of inflammatory bowel disease)
- IT Polyoxyalkylenes, biological studies
 RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
 (derivs.; aminosalicylate derivs. for treatment of inflammatory bowel disease)
- IT Stability
 (enzymic degradation resistance; aminosalicylate derivs. for treatment of inflammatory bowel disease)
- IT Enzymes, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (enzymic degradation resistance; aminosalicylate derivs. for treatment of inflammatory bowel disease)
- IT Intestine, disease
 (inflammatory; aminosalicylate derivs. for treatment of inflammatory bowel disease)
- IT Drug delivery systems

- (prodrugs; aminosalicylate derivs. for treatment of inflammatory bowel disease)
- IT Carbohydrates, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(reducing sugars; aminosalicylate derivs. for treatment of inflammatory bowel disease)
- IT Glycoconjugates
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(with 5-aminosalicylic acid; aminosalicylate derivs. for treatment of inflammatory bowel disease)
- IT 25322-68-3D, PEG, derivs.
RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(aminosalicylate derivs. for treatment of inflammatory bowel disease)
- IT 123135-21-7P 709610-92-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(aminosalicylate derivs. for treatment of inflammatory bowel disease)
- IT 89-57-6D, 5-Aminosalicylic acid, derivs. 32785-92-5
709610-84-4 709610-85-5 709610-86-6
709610-87-7 709610-88-8 709610-89-9
709610-90-2 709610-91-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aminosalicylate derivs. for treatment of inflammatory bowel disease)
- IT 50-99-7, D-(+)-Glucose, reactions 89-57-6,
5-Aminosalicylic acid 7284-37-9, β -D-Glucosylamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(aminosalicylate derivs. for treatment of inflammatory bowel disease)
- IT 25322-68-3D, PEG, derivs.
RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(aminosalicylate derivs. for treatment of inflammatory bowel disease)
- RN 25322-68-3 HCAPLUS
- CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (9CI) (CA INDEX NAME)



- IT 123135-21-7P 709610-92-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(aminosalicylate derivs. for treatment of inflammatory bowel disease)
- RN 123135-21-7 HCAPLUS
- CN Benzoic acid, 5-(β -D-glucopyranosylamino)-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 709610-92-4 HCAPLUS

CN Benzoic acid, 5-[(2-amino-2-deoxy- β -D-glucopyranosyl)amino]-2-hydroxy-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 89-57-6D, 5-Aminosalicylic acid, derivs. 32785-92-5

709610-84-4 709610-85-5 709610-86-6

709610-87-7 709610-88-8 709610-89-9

709610-90-2 709610-91-3


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(aminosalicylate derivs. for treatment of inflammatory bowel disease)

RN 89-57-6 HCAPLUS


CN Benzoic acid, 5-amino-2-hydroxy- (9CI) (CA INDEX NAME)



RN 32785-92-5 HCAPLUS

CN D-Fructose, 1-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 709610-84-4 HCAPLUS

CN Benzoic acid, 5-[(4-O- α -D-glucopyranosyl- β -D-glucopyranosyl)amino]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 709610-85-5 HCAPLUS

CN Benzoic acid, 5-[(4-O- β -D-galactopyranosyl- β -D-glucopyranosyl)amino]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 709610-86-6 HCAPLUS

CN Benzoic acid, 5-[(4-O- β -D-glucopyranosyl- β -D-glucopyranosyl)amino]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 709610-87-7 HCAPLUS

CN Benzoic acid, 5-[[2-(acetylamino)-4-O-[2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]-2-deoxy- β -D-glucopyranosyl]amino]-2-hydroxy- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 709610-88-8 HCAPLUS

CN Benzoic acid, 5-(β -D-galactopyranosylamino)-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 709610-89-9 HCAPLUS

CN Benzoic acid, 5-[(6-deoxy-L-galactopyranosyl)amino]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 709610-90-2 HCAPLUS

CN Benzoic acid, 5-[[2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 709610-91-3 HCAPLUS

CN Benzoic acid, 5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 50-99-7, D-(+)-Glucose, reactions 89-57-6,
5-Aminosalicyclic acid 7284-37-9, β-D-Glucosylamine

RL: RCT (Reactant); RACT (Reactant or reagent)
(aminosalicylate derivs. for treatment of inflammatory bowel disease)

RN 50-99-7 HCAPLUS


CN D-Glucose (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 89-57-6 HCAPLUS


CN Benzoic acid, 5-amino-2-hydroxy- (9CI) (CA INDEX NAME)



RN 7284-37-9 HCAPLUS

CN β -D-Glucopyranosylamine (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L58 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:11110 HCAPLUS

DN 136:64171

ED Entered STN: 04 Jan 2002

TI Novel breakers of advanced glycation endproducts

IN Rahbar, Samuel

PA City of Hope, USA

SO U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U.S. Ser. No. 626,859.

CODEN: USXXCO

DT Patent

LA English

IC ICM A61K031-196

ICS A61K031-195; A61K031-192; A61K031-155

INCL 514561000

CC 1-12 (Pharmacology)

FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002002203	A1	20020103	US 2001-825925	20010405
	US 6787566	B2	20040907		

US 6337350	B1	20020108	US 2000-543703	20000405
US 6589944	B1	20030708	US 2000-626859	20000727
US 2002013256	A1	20020131	US 2001-800976	20010308
US 6605642	B2	20030812		
CA 2439791	AA	20021003	CA 2002-2439791	20020305
WO 2002076443	A1	20021003	WO 2002-US6692	20020305
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1372627	A1	20040102	EP 2002-728413	20020305
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004529126	T2	20040924	JP 2002-574958	20020305
US 2002123501	A1	20020905	US 2002-96580	20020314
US 2002128278	A1	20020912	US 2002-96579	20020314
US 6693106	B2	20040217		
PRAI US 1999-127835P	P	19990405		
US 1999-131675P	P	19990429		
US 2000-543703	A2	20000405		
US 2000-559913	A2	20000428		
US 2000-626859	A2	20000727		
US 2001-800976	A2	20010308		
US 2001-825925	A	20010405		
WO 2002-US6692	W	20020305		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2002002203	ICM	A61K031-196
	ICS	A61K031-195; A61K031-192; A61K031-155
	INCL	514561000
US 2002002203	NCL	514/563.000; 514/571.000; 562/439.000
	ECLA	A23L003/3526; A61K031/155; A61K031/167; A61K031/17; A61K031/192; A61K031/195; A61K031/196; A61K031/198; A61K031/435; A61K031/4439; A61K031/522; A61K031/60G
US 6337350	NCL	514/596.000; 514/601.000; 546/257.000; 549/029.000; 549/229.000; 560/001.000; 560/008.000; 560/018.000; 560/027.000; 560/034.000; 560/053.000; 562/425.000; 562/426.000; 562/439.000; 562/440.000; 562/452.000; 562/455.000
	ECLA	A61K031/155; A61K031/192; A61K031/60G
US 6589944	NCL	514/166.000; 514/562.000; 514/563.000; 514/564.000; 514/567.000; 514/635.000; 514/878.000
	ECLA	A61K031/155; A61K031/192; A61K031/196; A61K031/198; A61K031/4439; A61K031/522; A61K031/60G
US 2002013256	NCL	514/563.000; 514/330.000; 514/564.000; 514/567.000; 546/191.000; 562/439.000; 562/455.000; 562/457.000
	ECLA	A61K031/155; A61K031/167; A61K031/17; A61K031/192; A61K031/195; A61K031/198; A61K031/435; A61K031/60G
WO 2002076443	ECLA	A61K031/155; A61K031/195; A61K031/198; A61K031/60G
JP 2004529126	FTERM	4C086/AA01; 4C086/AA02; 4C086/DA17; 4C086/MA01; 4C086/MA04; 4C086/MA09; 4C086/MA10; 4C086/NA14; 4C086/ZA01; 4C086/ZA16; 4C086/ZA45; 4C086/ZA81; 4C086/ZA96; 4C086/ZB15; 4C086/ZC35; 4C206/AA01; 4C206/AA02; 4C206/HA30; 4C206/HA31; 4C206/JA61;

4C206/KA01; 4C206/MA01; 4C206/MA04; 4C206/NA14;
 4C206/ZA01; 4C206/ZA16; 4C206/ZA45; 4C206/ZA81;
 4C206/ZA96; 4C206/ZB15; 4C206/ZC35

US 2002123501 NCL 514/263.360; 514/369.000; 514/635.000
 ECLA A61K031/155; A61K031/60G; A61K031/196; A61K031/198;
 A61K031/4439; A61K031/522

US 2002128278 NCL 514/263.340; 514/263.360; 514/263.380; 514/369.000
 ECLA A61K031/155; A61K031/196; A61K031/198; A61K031/4439;
 A61K031/522; A61K031/60G

AB Advanced glycation endproducts (AGEs) have been implicated in the pathogenesis of a variety of debilitating diseases such as diabetes, atherosclerosis, Alzheimer's and rheumatoid arthritis, as well as in the normal aging process. Seven compds. are here reported to be active in breaking AGE-protein cross-links. These compds. are 1,4-benzene-bis[4-methyleneaminophenoxyisobutyric acid] (LR102); 4-[3,5-dichlorophenylureidophenoxyisobutyryl]-4-aminobenzoic acid (LR99); L-bis-[4-(4-chlorobenzamidophenoxyisobutyryl)cystine] (LR20); 4-(3,5-dichlorophenylureido)phenoxyisobutyryl-1-amidocyclohexane-1-carboxylic acid (LR23); methylene bis[4,4'-(2-chlorophenylureidophenoxyisobutyric acid)] (LR90); 5-aminosalicylic acid (5-ASA); and metformin. These compds. may be used to reverse the debilitating effects of those diseases in which AGEs are formed. The AGE breakers developed in our laboratory were effective in cleaving AGE crosslinks in the tail of diabetic rats. Furthermore, several of the compds. were capable of breaking IgG-AGE crosslinks on the surface of red blood cells, as well as disaggregating both fibrillar forms of both native and glycated β -amyloid. Among the LR series of compds., we found LR-23 and LR-102 as the most effective AGE-breakers.

ST breaker advanced glycation endproduct protein crosslink; diabetes advanced glycation endproduct cleavage compd; atherosclerosis AGEs protein crosslink cleavage compd; Alzheimer advanced glycation endproduct cleavage compd; rheumatoid arthritis advanced glycation endproduct cleavage compd; aging advanced glycation endproduct cleavage compd; IgG crosslinks AGE red blood cell cleavage; glycated beta amyloid disaggregation AGEs breaker

IT Glycoproteins
 RL: ADV (Adverse effect, including toxicity); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
 (AGE (advanced glycosylation end product); novel breakers of advanced glycation endproducts)

IT Erythrocyte
 (AGE-modified IgG crosslinked to, AGE-breakers cleavage of; novel breakers of advanced glycation endproducts)

IT Antibodies and Immunoglobulins
 RL: ADV (Adverse effect, including toxicity); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
 (IgG, AGE-modified and crosslinked to red blood cells, AGE-breakers cleavage of; novel breakers of advanced glycation endproducts)

IT Aging, animal
 Alzheimer's disease
 Atherosclerosis
 Diabetes mellitus
 Rheumatoid arthritis
 (cleavage of AGEs associated with; novel breakers of advanced glycation endproducts)

IT Collagens, preparation
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (crosslinked with AGE-BSA, cleavage of; novel breakers of advanced glycation endproducts)

IT Proteins

RL: ADV (Adverse effect, including toxicity); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
 (crosslinked, with AGEs, cleavage of; novel breakers of advanced glycation endproducts)

IT Kidney, disease
 (failure, reversing progress of; novel breakers of advanced glycation endproducts)

IT Human
 (novel breakers of advanced glycation endproducts)

IT Nerve
 (reversing progress of; novel breakers of advanced glycation endproducts)

IT Albumins, preparation
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (serum, glycated and crosslinked, AGE-breakers cleavage of; novel breakers of advanced glycation endproducts)

IT Nerve
 (toxicity, reversing progress of; novel breakers of advanced glycation endproducts)

IT Disease, animal
 (treatment of AGEs-associated; novel breakers of advanced glycation endproducts)

IT Amyloid
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (β -, AGE-modified, AGE-breakers disaggregation of; novel breakers of advanced glycation endproducts)

IT 249513-66-4, LR 20
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (LR 20; novel breakers of advanced glycation endproducts)

IT 249513-69-7, LR 23
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (LR 23; novel breakers of advanced glycation endproducts)

IT 245075-84-7, LR 90
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (LR 90; novel breakers of advanced glycation endproducts)


IT 89-57-6, 5-Aminosalicylic acid 657-24-9, 1,1-Dimethylbiguanide 385437-91-2, LR 102
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (novel breakers of advanced glycation endproducts)

IT 89-57-6, 5-Aminosalicylic acid 657-24-9, 1,1-Dimethylbiguanide 385437-91-2, LR 102
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (novel breakers of advanced glycation endproducts)

RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE

- (1) Al-Abed, Y; Proc. Natl. Acad. Sci. USA 1999, V96, P2385 HCAPLUS
- (2) Anon; WO 9207560 A1 1992
- (3) Anon; WO 9531192 1995 HCAPLUS
- (4) Anon; WO 0059875 A2 2000 HCAPLUS
- (5) Asif, M; PNAS 2000, V97(6), P2809 HCAPLUS
- (6) Boel, E; J. Diabetes and its Complications 1995, V9, P104 MEDLINE
- (7) Booth, A; Biochem. Biophys. Res. Commun. 1996, V220, P113 HCAPLUS
- (8) Booth, A; Journal of Biological Chemistry 1997, V272(9), P5430 HCAPLUS

- (9) Calatayud, J; Math and Find Exptl Clin Pharmacol 1983, V5(10), P707 HCAPLUS
 (10) Cameron, N; Diabetologia 1992, V35, P946 HCAPLUS
 (11) Cooper, M; Diabetologia 2000, V43, P660 HCAPLUS
 (12) Corbett, J; Diabetes 1992, V41, P552 HCAPLUS
 (13) Durany, N; Eur. Arch. Psychiatry Clin. Neurosci. 1999, V249(Suppl. 3), PIII/68
 (14) Hirsch, J; Carbohydrate Research 1992, V232, P125 HCAPLUS
 (15) Jakus, V; Life Sciences 1999, V65, P18
 (16) Jyothirmayi, G; J. Cardiovasc. Pharmacol. Therapeut. 1998, V3(4), P319 HCAPLUS
 (17) Khalifah, R; Biochem. Biophys. Res. Commun 1999, P257
 (18) Kochakian, M; Diabetes 1996, V45, P1694 HCAPLUS
 (19) Lankin; US 5661139 A 1997 HCAPLUS
 (20) Malik, N; Biochem. Biophys. Res. Commun. 1994, V199(2), P683 HCAPLUS
 (21) Marques, C; Documenta Ophthalmologica 1995, V90, P395 MEDLINE
 (22) Menzel, E; Ann. Clin. Biochem. 1996, V33, P241 HCAPLUS
 (23) Miwa, I; Pharmacology 1996, V52, P314 HCAPLUS
 (24) Morimitsu, Y; Biosci. Biotech. Biochem. 1995, V59(11), P2018 HCAPLUS
 (25) Muench, G; Biochimica et Biophysica Acta 1997, V1360, P17 HCAPLUS
 (26) Muench, G; Brain Research Reviews 1997, V23, P134 HCAPLUS
 (27) Nakamura, S; Diabetes 1997, V46, P895 MEDLINE
 (28) Rahbar, S; Biochem. Biophys. Res. Commun. 1999, V262, P651 HCAPLUS
 (29) Rahbar, S; Clinica Chimica Acta 1999, V287, P123 HCAPLUS
 (30) Raj, D; American Journal of Kidney Diseases 2000, V35(3), P365 HCAPLUS
 (31) Ruggiero-Lopez, D; Biochem. Pharmacology 1999, V58, P1765 HCAPLUS
 (32) Ryan, M; Adv. Dent. Res 1998, V12, P152 MEDLINE
 (33) Sensi, M; Diabetologia 1993, V36, P797 HCAPLUS
 (34) Soulis, T; Diabetologia 1997, V40, P1141 HCAPLUS
 (35) Soulis, T; Diabetologia 1999, V42, P472 HCAPLUS
 (36) Swamy-Mruthinti, S; Exp. Eye Res. 1999, V69, P109 HCAPLUS
 (37) Taguchi, T; European Journal of Pharmacology 1999, V378, P283 HCAPLUS
 (38) Tanaka, Y; European Journal of Pharmacology 1999, V376, P17 HCAPLUS
 (39) Thornally, P; Biochemical Pharmacology 1999, V57, P303
 (40) Tilton, R; Diabetes 1993, V42, P221 HCAPLUS
 (41) Tsuchida, K; Diabetologia 1999, V42, P579 HCAPLUS
 (42) Ulrich; US 5272176 A 1993 HCAPLUS
 (43) Ulrich, P; Diabetologia 1997, V40, P157
 (44) Van Boekel, M; Biochimica et Biophysica Acta 1992, V1120, P201 HCAPLUS
 (45) Vasan, S; Nature 1996, V382, P275 HCAPLUS
 (46) Wolffenbuttel, B; Proc. Natl. Acad. Sci. USA 1998, V95, P4630 HCAPLUS
- IT 89-57-6, 5-Aminosalicylic acid
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (novel breakers of advanced glycation endproducts)
- RN 89-57-6 HCAPLUS
 CN Benzoic acid, 5-amino-2-hydroxy- (9CI) (CA INDEX NAME)




IT 50-99-7, D-Glucose, reactions
 RL: RCT (Reactant); RACT (Reactant or reagent)

(novel breakers of advanced glycation endproducts)

RN 50-99-7 HCAPLUS

CN D-Glucose (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



L58 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:614766 HCAPLUS

DN 131:295292

ED Entered STN: 26 Sep 1999

TI Antiulcer effect of the N- and O-β-D-glucopyranosides of 5-aminosalicylic acid

AU Sztaricskai, Ferenc; Takacs, Ildiko E.; Pusztai, Ferenc; Szabo, Gabor; Csipo, Istvan

CS Research Group Antibiotics, Lajos Kossuth Univ., Hungarian Academy Sciences, Debrecen, H-4010, Hung.

SO Archiv der Pharmazie (Weinheim, Germany) (1999), 332(9), 321-326 CODEN: ARPMAS; ISSN: 0365-6233

PB Wiley-VCH Verlag GmbH

DT Journal

LA English

CC 1-7 (Pharmacology)

Section cross-reference(s): 25, 33

AB Starting from Me 5-nitrosalicylate, 5-aminosalicylic acid as well as its N- and O-β-glucopyranosides (I and II, resp.) were prepared. The LD50 values of these compds. were determined on mice, and the inhibitory effect of I and II (0.83 and 1.2 mmol/kg, resp.) on indomethacin-induced gastric ulcer was investigated in rats.

ST aminosalicylate glucopyranoside antiulcer prepn

IT Antiulcer agents

(preparation and antiulcer activity of aminosalicylate glucopyranosides)

IT 89-57-6P, 5-Aminosalicylic acid 135790-62-4P 135790-65-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and antiulcer activity of aminosalicylate glucopyranosides)

IT 50-99-7, D-Glucose, reactions 69-72-7, Salicylic acid, reactions 96-97-9, 5-Nitrosalicylic acid 572-09-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation and antiulcer activity of aminosalicylate glucopyranosides)

IT 17302-46-4P, Methyl 5-nitrosalicylate 61294-22-2P 90922-94-4P 135790-64-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and antiulcer activity of aminosalicylate glucopyranosides)

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Agback, K; DB 2257629 1971

(2) Allgayer, H; Eur J Clin Pharmacol 1984, V26, P449 HCAPLUS

(3) Anon; CH 632670 1977 HCAPLUS

(4) Barany, H; J Chem Soc 1946, P965 HCAPLUS

- (5) Bognar, R; Magy Kem Foly 1953, V59, P185
- (6) Bouley, E; J Med Chem 1986, V29, P100 HCAPLUS
- (7) DelSoldato, P; Agent Actions 1985, V16, P393 HCAPLUS
- (8) Evans, E; DB 722795 1950
- (9) Ezer, E; J Pharm Pharmacol 1981, V33, P250 HCAPLUS
- (10) Fischer, A; Chem Ber 1899, V32, P81
- (11) Gaspar, I; HU 22210/88 1988
- (12) Gaspar, I; HU 22211/88 1988
- (13) Grandmougin, E; Chem Ber 1906, V39, P3929
- (14) Hirsch, R; Chem Ber 1900, V33, P3238
- (15) Khan, A; Clin Sci 1983, V64, P349 HCAPLUS
- (16) Khan, A; Lancet 1977, V2, P892
- (17) Klotz, U; Digest Dis Sci 1987, V32, P465
- (18) Konishi, M; J Antib 1985, V38, P1605 HCAPLUS
- (19) Litchfield, J; J Pharmacol Exp Ther 1949, V96, P99 HCAPLUS
- (20) Nagy, E; J Chromat 1988, V425, P214 HCAPLUS
- (21) Parkinson, T; US 4190716 1980 HCAPLUS
- (22) Peppercorn, M; J Pharm Exp Ther 1972, V181, P595
- (23) Peskar, B; Digest Dis Sci 1987, V32, P516
- (24) Prudhomme, M; J Antib 1986, V39, P923
- (25) Puxeddu, N; Gaz Chim Ital 1929, V59, P12
- (26) Rainsford, K; Gut 1975, V16, P514 HCAPLUS
- (27) Rasmussen, S; Gastroenterology 1983, V85, P1350 MEDLINE
- (28) Robertson, A; J Chem Soc 1930, P2729 HCAPLUS
- (29) Rokos, H; DB 3323702 1983
- (30) Sarett, L; GB 1359560 1972 HCAPLUS
- (31) Sasaki, T; Tetrahedron Lett 1981, V27, P1603
- (32) Stenson, W; Biochem Pharmacol 1983, V32, P2205 HCAPLUS
- (33) Taborsky, R; US 3278372 1965 HCAPLUS
- (34) Takai, H; J Antib 1976, V29, P1253 HCAPLUS
- (35) Turner, R; Screening Methods in Pharmacology 1965
- (36) Wasserman, H; J Am Chem Soc 1985, V107, P1423 HCAPLUS
- (37) Yin, M; Nature 1998, V396, P77 HCAPLUS


IT 89-57-6P, 5-Aminosalicylic acid

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and antiulcer activity of aminosalicylate glucopyranosides)

RN 89-57-6 HCAPLUS

CN Benzoic acid, 5-amino-2-hydroxy- (9CI) (CA INDEX NAME)



IT 50-99-7, D-Glucose, reactions


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation and antiulcer activity of aminosalicylate glucopyranosides)

RN 50-99-7 HCAPLUS


CN D-Glucose (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



L58 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1991:647335 HCAPLUS
 DN 115:247335
 ED Entered STN: 14 Dec 1991
 TI Stability of 5-aminosalicylic acid and its metabolites in plasma at
 -20°C: formation of N-β-D-glucopyranosyl-5-aminosalicylic acid
 AU Tjoernelund, Jette; Hansen, Steen Honore
 CS PharmaBiotech Res. Cent., R. Dan. Sch. Pharm., Copenhagen, DK-2100, Den.
 SO Journal of Chromatography (1991), 570 (1), 224-8
 CODEN: JOCRAM; ISSN: 0021-9673
 DT Journal
 LA English
 CC 1-1 (Pharmacology)
 AB The stability of 5-aminosalicylic acid and its metabolites has been
 investigated when stored frozen. N-β-D-Glucopyranosyl-5-
 aminosalicylic acid was formed in considerable amts. concomitant with a
 decrease in 5-aminosalicylic acid in plasma samples spiked with
 5-aminosalicylic acid as well as in standard solns. of 5-aminosalicylic acid
 buffered with potassium phosphate between pH 5.5 and pH 8.0 with 4.0 mM
 glucose added and stored at -20°. Thus N-β-D-glucopyranosyl-5-
 aminosalicylic acid might not, as previously described, be a metabolite of
 5-aminosalicylic acid but an artifact formed during storage of plasma
 samples. The N-glucoside formed could be quant. degraded to
 5-aminosalicylic acid and glucose by adding 0.2 M potassium phosphate
 buffer pH 3.0 to the sample prior to the anal. The metabolites of
 5-aminosalicylic acid (N-formyl-5-aminosalicylic acid,
 N-acetyl-5-aminosalicylic acid and N-butyryl-5-aminosalicylic acid) were
 found to be stable in plasma stored at -20° for at least eight
 months.
 ST aminosalicylate metabolite stability glucoside blood preservation
 IT Blood preservation
 (by freezing, stability of aminosalicylic acid and its metabolites in,
 glucoside formation in)
 IT 123135-21-7
 RL: FORM (Formation, nonpreparative)
 (formation of, from aminosalicylic acid in frozen blood plasma)
 IT 89-57-6, 5-Aminosalicylic acid
 RL: BIOL (Biological study)
 (stability of metabolites of and, in frozen blood plasma, glucoside
 formation in)
 IT 51-59-2, N-Acetyl-5-aminosalicylic acid 93968-81-1 104786-99-4
 RL: PRP (Properties)
 (stability of, in frozen blood plasma, as aminosalicylic acid
 metabolite)
 IT 123135-21-7
 RL: FORM (Formation, nonpreparative)
 (formation of, from aminosalicylic acid in frozen blood plasma)
 RN 123135-21-7 HCAPLUS
 CN Benzoic acid, 5-(β-D-glucopyranosylamino)-2-hydroxy- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



L58 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1991:647332 HCAPLUS
 DN 115:247332
 ED Entered STN: 14 Dec 1991
 TI High-performance liquid chromatographic assay of 5-aminosalicylic acid (5-ASA) and its metabolites N-β-D-glucopyranosyl-5-ASA, N-acetyl-5-ASA, N-formyl-5-ASA and N-butyryl-5-ASA in biological fluids
 AU Tjoernelund, Jette; Hansen, Steen Honore
 CS PharmaBiotech Res. Cent., R. Dan. Sch. Pharm., Copenhagen, DK-2100, Den.
 SO Journal of Chromatography (1991), 570(1), 109-17
 CODEN: JOCRAM; ISSN: 0021-9673
 DT Journal
 LA English
 CC 1-1 (Pharmacology)
 AB A fast, highly sensitive HPLC method for the simultaneous determination of 5-aminosalicylic acid (5-ASA) and its metabolites N-β-D-glucopyranosyl-5-ASA, N-formyl-5-ASA, N-acetyl-5-ASA and N-butyryl-5-ASA has been developed using a dynamically modified silica approach on a 40 mm + 4.6 mm I.D. column packed with 3-μm Hypersil. Plasma proteins are precipitated with acetonitrile. After extraction of the acetonitrile into 1,1,1-trichloroethane, an undiluted aqueous phase containing the analytes is obtained. The detection limits are in the range 0.002-0.05 μg/mL in plasma at a signal-to-noise ratio of 3 using fluorescence detection.
 ST aminosalicylate metabolite detn blood urine HPLC; liq chromatog
 aminsalicylate metabolite blood urine
 IT Blood analysis
 Urine analysis
 (aminosalicylic acid and metabolites determination in, by HPLC)
 IT Chromatography, column and liquid
 (high-performance, of aminosalicylic acid and its metabolites, in blood and urine determination)
 IT 89-57-6, 5-Aminosalicylic acid
 RL: BIOL (Biological study)
 (determination of metabolites of and, in blood and urine by HPLC)
 IT 51-59-2, N-Acetyl-5-aminosalicylic acid 93968-81-1 104786-99-4
 123135-21-7
 RL: ANT (Analyte); ANST (Analytical study)
 (determination of, as aminosalicylate metabolite, in blood and urine by HPLC)


L58 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1991:559545 HCAPLUS
 DN 115:159545
 ED Entered STN: 18 Oct 1991
 TI 5-Aminosalicylic acid and its glucopyranosyl derivatives

I
II


jan delaval - 10 august 2005

(preparation and saponification of)
 IT 135790-62-4P 135790-65-7P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (preparation and solubility of, in water)
 IT 51-59-2P, 5-(Acetamido)salicylic acid
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 IT 51-59-2P, 5-(Acetamido)salicylic acid
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 IT 50-99-7, D-Glucose, reactions
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (glycosylation with, of aminosalicylic acid derivative)
 RN 50-99-7 HCAPLUS
 CN D-Glucose (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 89-57-6P, 5-Aminosalicylic acid
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of glucopyranoside prodrug derivs. of)
 RN 89-57-6 HCAPLUS
 CN Benzoic acid, 5-amino-2-hydroxy- (9CI) (CA INDEX NAME)



L58 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1989:566711 HCAPLUS
 DN 111:166711
 ED Entered STN: 10 Nov 1989
 TI New metabolites of the drug 5-aminosalicylic acid. I:
 N-β-D-glucopyranosyl-5-aminosalicylic acid
 AU Tjoernelund, J.; Hansen, S. H.; Cornett, C.
 CS Pharmabiotec Res. Cent., R. Dan. Sch. Pharm., Copenhagen, DK-2100, Den.
 SO Xenobiotica (1989) 19(8) 891-9
 CODEN: XENOBH; ISSN: 0049-8254
 DT Journal
 LA English
 CC 1-2 (Pharmacology)
 GI



AB A new unstable metabolite of 5-aminosalicylic acid (I) was found in plasma from healthy volunteers dosed with I i.v. The metabolite was prepared by incubation of I with rat liver homogenate, and isolated by preparative HPLC. The metabolite was identified as N-β-D-glucopyranosyl-5-aminosalicylic acid (II) by NMR spectroscopy and by FAB mass spectrometry. II was formed non-enzymically from I and glucose in phosphate buffer pH 7.4, and was unstable under weakly acidic conditions; decomposition increased with temperature, i.e. decomposition was complete after 30 min at pH 5.0 and 23°.

ST aminosalicylate metab glucopyranosylaminosalicylate

IT Liver, metabolism
(aminosalicylic acid metabolism to glucopyranosylaminosalicylic acid in)

IT 123135-21-7
RL: BIOL (Biological study)
(as aminosalicylate acid metabolite, in humans and laboratory animals)


IT 123135-21-7
RL: BIOL (Biological study)
(as aminosalicylate acid metabolite, in humans and laboratory animals)

IT 123135-21-7
RL: BIOL (Biological study)
(as aminosalicylate acid metabolite, in humans and laboratory animals)

RN 123135-21-7 HCAPLUS

CN Benzoic acid, 5-(β-D-glucopyranosylamino)-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L58 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1986:565010 HCAPLUS

DN 105:165010

ED Entered STN: 15 Nov 1986

TI Aminosalicylate acid derivatives and pharmaceutical compositions

IN Sportoletti, Giancarlo

PA Italfarmaco S.p.A., Italy

SO PCT Int. Appl., 34 pp.


CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07D233-56
 ICS C07C103-46; C07D213-56; C07H013-12; C07D233-58; C07C103-50;
 C07C103-82; A61K031-60
 CC 1-7 (Pharmacology)
 Section cross-reference(s): 25, 63
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8603199	A1	19860605	WO 1985-EP645	19851126
	W: AU, BG, BR, DK, FI, HU, JP, KP, KR, NO, RO, SU, US				
	RW: AT, BE, CF, CG, CH, CM, DE, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	AU 8652311	A1	19860618	AU 1986-52311	19851126
	ZA 8509035	A	19860827	ZA 1985-9035	19851126
	JP 62501703	T2	19870709	JP 1986-500163	19851126
	EP 236329	A1	19870916	EP 1986-900097	19851126
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	CN 85109554	A	19860723	CN 1985-109554	19851127
	ES 549359	A1	19861201	ES 1985-549359	19851128
	DK 8603464	A	19860721	DK 1986-3464	19860721
PRAI	IT 1984-23799	A	19841129		
	WO 1985-EP645	A	19851126		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 8603199	ICM	C07D233-56
	ICS	C07C103-46; C07D213-56; C07H013-12; C07D233-58; C07C103-50; C07C103-82; A61K031-60

GI



AB 5-Acylamino-2-hydroxybenzoic acid derivs. (I, B = H, imidazolium, lysine or methylglycoamine, R = H, C1-25 alkyl, aryl groups, heterocyclic groups) have antiinflammatory, antiaggregating and antithrombotic properties. 5-(2,4-Dichlorobenzoylamino)-2-hydroxybenzoic acid was prepared from 5-aminosalicylic acid and 2,4-Cl₂C₆H₃COCl and was converted to its imidazole salt. I showed soy lipoxygenase inhibition, platelet aggregation and thromboxane A₂ production, and antiinflammatory activities with the salts usually showing higher activities.

ST aminosalicylate pharmaceutical; inflammation inhibitor aminosalicylate; antithrombotic aminosalicylate; imidazole aminosalicylate salt

IT Anticoagulants and Antithrombotics
 Inflammation inhibitors and Antiarthritics
 (acylamino-2-hydroxybenzoic acid derivs.)

IT Blood platelet
 (aggregation of, inhibitors, acylamino-2-hydroxybenzoic acid derivs. as)

IT 89-75-8 112-67-4

RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation by, of aminosalicyclic acid)

IT 89-57-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation of)

IT 51-59-2P 28772-37-4P 32194-66-4P 79049-98-2P 99450-63-2P
104786-89-2P 104786-90-5P 104786-91-6P 104786-92-7P 104786-93-8P
104786-94-9P 104786-95-0P 104786-96-1P 104786-97-2P
104786-98-3P 104786-99-4P 104787-00-0P 104787-01-1P
104787-02-2P 104787-03-3P 104787-04-4P 104787-05-5P 104787-06-6P
104787-07-7P 104787-08-8P 104787-09-9P 104787-10-2P 104787-11-3P
104787-12-4P 104787-13-5P 104787-14-6P 104787-15-7P 104787-16-8P
104787-17-9P 104787-18-0P 104787-19-1P 104787-20-4P 104787-21-5P
104787-23-7P **104787-24-8P** 104787-25-9P 104787-26-0P
104787-27-1P 104787-28-2P 104787-29-3P 104787-30-6P 104787-31-7P
104787-32-8P 104787-33-9P 104814-00-8P 104814-01-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for pharmaceuticals)


IT **104786-98-3P 104787-24-8P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for pharmaceuticals)

RN 104786-98-3 HCAPLUS

CN Benzoic acid, 5-(D-glucuronoylamino)-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 104787-24-8 HCAPLUS


CN Benzoic acid, 5-(D-glucuronoylamino)-2-hydroxy-, compd. with 1H-imidazole
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 104786-98-3

CMF C13 H15 N O9


Absolute stereochemistry.



CM 2

CRN 288-32-4

CMF C3 H4 N2



=> d his

(FILE 'HOME' ENTERED AT 11:16:54 ON 10 AUG 2005)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 11:17:04 ON 10 AUG 2005

L1 1 S US20040121967/PN OR (US2003-688585# OR US2002-435964#)/AP,PRN
SEL RN

FILE 'REGISTRY' ENTERED AT 11:17:31 ON 10 AUG 2005

L2 15 S E1-E15
L3 STR
L4 50 S L3 CSS
L5 3704 S L3 CSS FUL
SAV L5 WHITE688/A
L6 18 S L5 AND OC5/ES
L7 8 S L6 AND ((PMS OR MXS)/CI OR C15H19NO8 OR C24H33NO9 OR C22H30N2
L8 10 S L6 NOT L7
SAV L8 WHITE688A/A
L9 14 S L5 AND C2H4O
L10 STR L3
L11 0 S L10 SAM SUB=L5
L12 0 S L10 FUL SUB=L5
SAV L12 WHITE688B/A
L13 STR L3
L14 0 S L13 SAM SUB=L5
L15 3 S L13 FUL SUB=L5
SAV L15 WHITE688C/A
L16 2 S L15 NOT NC5/ES

FILE 'HCAOLD' ENTERED AT 11:35:42 ON 10 AUG 2005
L17 0 S L8 OR L16

FILE 'HCAPLUS' ENTERED AT 11:35:48 ON 10 AUG 2005
L18 5 S L8 OR L16
E NELSON D/AU
L19 185 S E3,E16
E NELSON DEANA/AU
L20 47 S E4-E7
L21 1 S L18 AND L19,L20
L22 5 S L18,L21

FILE 'USPATFULL' ENTERED AT 11:36:58 ON 10 AUG 2005
L23 1 S L8 OR L16

FILE 'REGISTRY' ENTERED AT 11:37:04 ON 10 AUG 2005
E DEOXYMALTOBIOSE/CN
E 1-DEOXYMALTOBIOSE/CN
E 1-DEOXYLACTOBIOSE/CN
E DEOXYLACTOBIOSE/CN
E DEOXYCELLOBIOSE/CN
E N,N-DIACETYL-1-DEOXYCHITOBIOSE/CN
E 1-DEOXYGLUCOSE/CN
E 1-DEOXYGALACTOSE/CN
E 1-DEOXYFUCOSE/CN
E 1-DEOXYFRUCTOSE/CN
L24 1 S E3
E N-ACETYL-1-DEOXYGLUCOSAMINE/CN
E N-ACETYL-1-DEOXYGALACTOSEAMINE/CN
L25 9 S (MALTOBIOISE OR LACTOBIOSE OR CELLOBIOISE OR GLUCOSE OR GALAC
E N-ACETYL-1-GLUCOSAMINE/CN
E N-ACETYL-GLUCOSAMINE/CN
E N-ACETYLGLUCOSAMINE/CN
L26 1 S E3
E N-ACETYLALACTOSAMINE/CN
L27 2 S E3
L28 4 S (L-GLUCOSE OR L-GALACTOSE OR D-FUCOSE OR L-FRUCTOSE)/CN
E C8H15NO6/MF
L29 16 S E3 AND GLUCOSE AND 2' ACETYLAMINO 2 DEOXY
L30 8 S L29 NOT ((T OR D)/ELS OR OC5/ES)
L31 2 S L30 NOT (LABELED OR 13C# OR 14C#)
L32 8 S E3 AND GALACTOSE AND 2 ACETYLAMINO 2 DEOXY
L33 3 S L32 NOT (LABELED OR (T OR D)/ELS OR 13C# OR 14C#)
L34 1 S L2 AND C6H12O5
L35 1 S L2 AND C6H13NO5
E C6H13NO5/MF
L36 3 S E3 AND GLUCOPYRANOSYLAMINE
E LACTOBIOSE/CN
L37 1 S E3
E C12H22O11/MF
L38 21 S E3 AND GLUCOSE AND GALACTOPYRANOSYL
L39 12 S L38 AND 4
L40 2 S L39 NOT (LABELED OR 14C# OR (T OR D)/ELS OR 13C#)
E MALTOBIOSE/CN
L41 1 S E3
E C12H22O11/MF
L42 14 S E3 AND GLUCOSE AND GLUCOPYRANOSYL AND 4
L43 8 S L42 NOT (LABELED OR (T OR D)/ELS OR 13C# OR 14C#)
L44 7 S L43 NOT 180
E CHITOBIOSE/CN

L45 1 S E5
E C16H28N2O11/MF
L46 8 S E3 AND GLUCOSE AND 2 ACETYLAMINO AND 2 DEOXY AND GLUCOPYRANOS
L47 2 S L46 AND 4
L48 1 S 89-57-6
L49 1 S 25322-68-3

FILE 'HCAPLUS' ENTERED AT 11:57:01 ON 10 AUG 2005

L50 1817 S L48
L51 54 S L49 AND L50
L52 53 S L25-L28,L31,L33-L37,L40,L41,L44,L45,L47 AND L50
L53 4 S L48 (L) RACT+NT/RL AND L51,L52
L54 2 S L49 (L) RACT+NT/RL AND L51
L55 6 S L25-L28,L31,L33-L37,L40,L41,L44,L45,L47 (L) RACT+NT/RL AND L52
L56 7 S L53-L55
L57 11 S L22,L56
SEL DN AN 5 6
L58 9 S L57 NOT E1-E6

FILE 'REGISTRY' ENTERED AT 12:00:33 ON 10 AUG 2005

FILE 'USPATFULL' ENTERED AT 12:02:45 ON 10 AUG 2005

FILE 'HCAPLUS' ENTERED AT 12:03:34 ON 10 AUG 2005

=>